Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism
Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) made waves Monday with the announcement of the completion of its groundbreaking BioHive-2 supercomputer, as well as the notable surge in its stock that followed.
Recursion Pharmicals, Inc.（納斯達克股票代碼：RXRX）週一宣佈其開創性的BioHive-2超級計算機竣工，隨後其股票大幅上漲，引起了轟動。
RXRX Price Action: Recursion Pharmaceutical shares closed at $9.48 on Monday, reflecting an impressive gain of 10.2% compared to the previous day's close, according to Benzinga Pro.
RXRX價格走勢：根據Benzinga Pro的數據，Recursion Pharmaceutical股價週一收於9.48美元，與前一天的收盤價相比上漲了10.2％。
What Happened: Recursion's stock surge came after the company announced the completion of its new Nvidia Corp (NASDAQ:NVDA)-powered AI supercomputer. The computer, called BioHive-2, is powered by 63 Nvidia H100 systems with a total of 504 Nvidia H100 Tensor Core GPUs, interconnected by Nvidia Quantum-2 InfiniBand networking.
發生了什麼：Recursion的股票飆升是在該公司宣佈完成其基於Nvidia Corp（納斯達克股票代碼：NVDA）的新型人工智能超級計算機之後發生的。這臺名爲 BioHive-2 的計算機由 63 個 Nvidia H100 系統提供動力，共有 504 個 Nvidia H100 Tensor Core GPU，由 Nvidia Quantum-2 InfiniBand 網絡互連。
Related Link: HSBC Analyst Sees Nvidia Stock Climbing Another 50% On Strong Pricing Power, AI Roadmap
相關鏈接：匯豐銀行分析師認爲，由於強勁的定價能力和人工智能路線圖，英偉達股價將再上漲50％
The completion of the supercomputer signifies a significant milestone for Recursion in its quest to revolutionize drug discovery through advanced computational methods. The company's innovative approach, coupled with the unveiling of this state-of-the-art supercomputer, has evidently resonated positively with investors, driving up demand for Recursion's shares.
超級計算機的建成標誌着Recursion尋求通過先進的計算方法徹底改變藥物發現的過程中的一個重要里程碑。該公司的創新方法，加上這款最先進的超級計算機的問世，顯然引起了投資者的積極共鳴，推動了對Recursion股票的需求。
"With BioHive-2 now online, we have significantly more computational horsepower to accelerate our use of our ever-growing dataset, extending our ability to train larger and more generalizable foundation models and AI agents to industrialize our drug discovery efforts," said Ben Mabey, chief technology officer at Recursion.
Recursion首席技術官本·馬比表示：“隨着BioHive-2現已上線，我們的計算能力要大大提高，可以加速我們對不斷增長的數據集的使用，從而擴展我們訓練更大、更具通用性的基礎模型和人工智能代理的能力，從而將我們的藥物發現工作工業化。”
Monday's trading activity saw Recursion's stock trade as high as $10.40, showcasing the heightened investor interest. With a market capitalization of $2.248 billion, Recursion Pharmaceuticals continues to capture attention within the pharmaceutical and technology sectors, fueled by its ambitious goals and pioneering advancements in AI-driven drug discovery.
在週一的交易活動中，Recursion的股票交易價格高達10.40美元，這表明投資者的興趣有所增加。Recursion Pharmicals的市值爲22.48億美元，在其雄心勃勃的目標和人工智能驅動的藥物發現方面的開創性進步的推動下，繼續引起製藥和技術領域的關注。
"Accelerated computing, combined with the power of generative AI, is propelling the pharmaceutical industry into a new, advanced era of drug discovery," said Rory Kelleher, global head of business development for life sciences at Nvidia.
英偉達生命科學業務發展全球主管羅裏·凱勒赫表示：“加速計算加上生成式人工智能的力量，正在推動製藥行業進入一個新的先進藥物發現時代。”
"BioHive-2, powered by NVIDIA DGX AI supercomputing, is poised to accelerate the development of additional industry-leading foundation models across biology, chemistry, and healthcare."
“由NVIDIA DGX AI超級計算提供支持的BioHive-2有望加快生物學、化學和醫療保健領域其他行業領先基礎模型的開發。”
Image: courtesy of Recursion Pharmaceuticals.
圖片：由 Recursion Pharmicals 提供。